![H. Perez](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
H. Perez
Director/Board Member at Presidio Pharmaceuticals, Inc.
H. Perez active positions
Companies | Position | Start | End |
---|---|---|---|
The University of California, San Francisco | Corporate Officer/Principal | - | - |
Presidio Pharmaceuticals, Inc.
![]() Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Director/Board Member | - | - |
Chief Executive Officer | - | - | |
President | - | - |
Career history of H. Perez
Former positions of H. Perez
Companies | Position | Start | End |
---|---|---|---|
ACCELERATED PHARMA INC | Chairman | 01/04/2015 | 01/02/2016 |
Independent Dir/Board Member | 01/04/2015 | 01/02/2016 | |
STATERA BIOPHARMA, INC. | Director/Board Member | 20/07/2006 | - |
Independent Dir/Board Member | 20/07/2006 | 07/06/2011 | |
Berlex Biosciences | Chief Executive Officer | 01/01/1993 | 01/01/2006 |
President | 01/01/1993 | 01/01/2006 | |
Naia Rare Diseases LLC
![]() Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Chief Executive Officer | 01/01/2014 | - |
Chairman | 01/01/2014 | - | |
Founder | 01/01/2014 | - | |
Celtaxsys, Inc.
![]() Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Director/Board Member | 07/06/2011 | 13/09/2013 |
Chairman | 13/09/2013 | - | |
HYPERION THERAPEUTICS INC | Director/Board Member | 02/07/2009 | - |
Bay City Capital LLC
![]() Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Corporate Officer/Principal | - | - |
Training of H. Perez
Universidad de Buenos Aires | Doctorate Degree |
Universidad Mariano Egaña | Undergraduate Degree |
Statistics
International
United States | 10 |
Argentina | 2 |
Chile | 2 |
Operational
Director/Board Member | 4 |
Chief Executive Officer | 3 |
Chairman | 3 |
Sectoral
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 8 |
---|---|
Cleveland BioLabs, Inc.
![]() Cleveland BioLabs, Inc. Pharmaceuticals: MajorHealth Technology Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. It focuses on oncology and acute radiation syndrome. It offers Entolimod, Mobilan, CBL0137, and SA-702. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY. | Health Technology |
Celtaxsys, Inc.
![]() Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
Hyperion Therapeutics, Inc.
![]() Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
Accelerated Pharma, Inc.
![]() Accelerated Pharma, Inc. Medical SpecialtiesHealth Technology Accelerated Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in development of pre-existing pharmaceutical products for the treatment of various cancer indications. It offers a platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications under the Picoplatin brand. The company was founded by Michael Fonstein, Ekaterina E. Nikolaevskaya and Dmitry Prudnikov in May 2014 and is headquartered in Westport, CT. | Health Technology |
Bay City Capital LLC
![]() Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
Presidio Pharmaceuticals, Inc.
![]() Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Health Technology |
Berlex Biosciences | |
Naia Rare Diseases LLC
![]() Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Health Services |
- Stock Market
- Insiders
- H. Perez
- Experience